Joerger, M <br/><br/>
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Mar 2011 
 - 567-574 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdq431  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cetuximab<br/>Cisplatin--administration & dosage<br/>Cost-Benefit Analysis<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Markov Chains<br/>Monte Carlo Method<br/>Neoplasm Staging<br/>Proportional Hazards Models<br/>Sensitivity and Specificity<br/>Survival Analysis<br/>Treatment Failure<br/>Vinblastine--administration & dosage<br/>Vinorelbine